Study to Evaluate Safety and Efficacy of Carrimycin for Treatment of Severe Coronavirus Disease 2019 (COVID-19) in Hospitalized Patients

  • STATUS
    Recruiting
  • days left to enroll
    34
  • participants needed
    300
  • sponsor
    Shenyang Tonglian Group CO., Ltd
Updated on 20 April 2022

Summary

This is a randomized, multicenter, placebo-controlled, double-blind clinical study in patients hospitalized due to severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection.

Description

Eligible 300 hospitalized patients with confirmed severe SARS-CoV-2 infection will be randomly assigned (1:1) to receive 14 days treatment of 400 mg carrimycin and standard of care (SOC) or placebo and SOC.

Details
Condition Coronavirus Disease 2019
Treatment Placebo, Carrimycin
Clinical Study IdentifierNCT04672564
SponsorShenyang Tonglian Group CO., Ltd
Last Modified on20 April 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

Patient with SARS-CoV-2 infection as determined by real time polymerase chain reaction (RT- PCR) or other commercial or public health assay in any specimen taken ≤ 4 days prior to randomization. Onset of symptoms of COVID-19 must be 14 or fewer days prior to randomization. Patient with a second SARS-CoV-2 episode after resolution of the initial infection may be enrolled if the initial infection had clearly resolved, re-infection is reconfirmed by RT-PCR and all other eligibility criteria are met
Female patient of childbearing potential and male patient with female partner of childbearing potential must agree to use at least one primary form of contraception for the duration of the study
Hospitalized patient who requires oxygen supplementation via either low-flow oxygen device (such as nasal cannula or face mask), high flow oxygen therapy (including high-flow nasal cannula), or non invasive ventilation to maintain peripheral oxygen saturation of at least 94%. The patient must have had such an oxygen requirement for 2 days or fewer at the time of Screening, and the oxygen requirement must be non-improving (worsening or stable) in the Investigator's judgement at the time of Screening and randomization
Ability to provide informed consent personally, or by a legally acceptable representative if the patient is unable to do so
Patient is willing and able to comply with all required study visits and follow up required by the protocol
Patient must agree not to enroll in another study of an investigational agent prior to completion of Day 60 of study

Exclusion Criteria

Non-hospitalized patients, including those requiring home oxygen support
Patient has a creatinine clearance < 50 mL/min/1.73m^2 using the modification of diet in renal disease formula
Patient has a known allergy to any study medication or macrolides
Patient cannot take the study drug by mouth and needs to be administered by nasogastric tube at Screening
Patient with known medical history of hepatitis B or, if tested, presence of hepatitis B surface antigen at Screening
Patient has a positive hepatitis C RNA test result at Screening
Patient has a known medical history of hepatitis C or positive hepatitis C antibody test result at Screening (if obtained)
Patient has been treated with anti-tumor therapy with immunosuppressive effects, which includes chemotherapy, biologics and hormonal therapy in the past 30 days prior to Screening
Patient has a known medical history of human immunodeficiency virus (HIV) infection or was seropositive for human immunodeficiency virus (if tested)
Patient has used a macrolide in the week prior to Screening
Patient has used antiviral drugs which are not part of SOC < 24 hours prior to Day 1
Patient receiving hemoperfusion or with anticipated use of hemoperfusion (including when hemoperfusion is a part of SOC)
Patient who, in the judgment of the Investigator, will be unlikely or unable to comply with the requirements of this protocol through Day 60
Patient has used the following types of medications < 2 days prior to Day 1 and/or plans to initiate such medications during the treatment period without an appropriate alternative therapy
Female patient who is pregnant or breastfeeding
Narrow therapeutic index substrates of cytochrome P450 (CYP) enzymes
Critical patient with a life expectancy < 48 hours
Narrow therapeutic index substrates of major transporters: organic anion transporting polypeptide 1B1 and 1B3 (OATP1B1, OATP1B3), organic anion transporter 1 and 3 (OAT1, OAT3), organic cation transporter 2 (OCT2) and multidrug and toxin extrusion proteins 1 and 2-K (MATE1, MATE2K)
Patient who has received an organ transplant in the past 6 months prior to Screening or is on the waiting list for organ transplantation
Strong inhibitors and/or inducers of enzymes CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP3A4/5
Patient with evidence of multiorgan failure (defined as two or more organs failing) or septic shock
Patient requiring mechanical ventilation or extracorporeal membrane oxygenation at Screening
Strong inhibitors of transporters OATP1B1 and OATP1B3
Note: strong inhibitors of OAT1/OAT3, OCT2 and MATE1/MATE2K should be avoided when possible, but when unavoidable investigators may assess the risks and benefits and to continue treatment with such medications under close observation for adverse events
Patient has a mean corrected QT interval using Fridericia's formula (QTcF) of > 450 msec (for male patients) and > 470 msec (for female patients) at Screening
Patient who has a history of alcohol abuse within 3 months prior to the study as judged by the Investigator
Patient has consumed foods and/or used herbal medicines with strong CYP3A4 or CYP3A5
effects
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note